Prysheng (Beijing) Pharmaceutical Technology Development Co., Ltd
Booth number:A23 Exhibits:medical service

Company Introduction:

Prexam (Beijing) Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as Prexam), founded in 2003, is a CRO company that can provide joint development of pharmaceutical affairs between China and the United States, the European Union, South Korea, Japan, Taiwan, China and other countries and regions. After 20 years of development, the company has successfully provided clinical research services for over 1800 projects to over 500 domestic and foreign pharmaceutical companies.

Primax has over 500 full-time employees, with offices located in over 30 cities including Beijing, Wuhan, Changsha, and Guangzhou. It also has subsidiaries in Shanghai and Qingdao, as well as branches in Guangzhou, Nanjing, and Shanghai. Primax is committed to providing comprehensive, internationally standardized, and fully utilizing regional resources for precise clinical services.

The company has a long history, early integration with international standards, and a high degree of internationalization. In 2012, we started offshore outsourcing services and collaborated with over 300 domestic Biotech companies in the United States. We have experience in multiple projects that have been submitted to FDA and EMA and have been approved. NMPA/FDA/EMA has been approved for over 160 products, most of which are innovative both domestically and internationally. In the research projects, there have been over 130 innovative drug projects in the past three years, of which 53% are cancer projects and hematoma projects, accounting for 20% of the national research and development projects.

The company team is stable, and the core personnel have a significant influence in the industry. More than 31% of employees have more than 5 years of industry experience, of which 2/3 are trained by Prudential; Employees with more than 5 years of experience account for 22%, while employees with more than 3 years of experience account for 35%. More than 100 people have been transferred to international CROs such as Jingding, and some have become senior management at the director level. They have trained over 500 digital talents for China's pharmaceutical research and development.

Customer satisfaction is high, with repurchase orders accounting for over 60%. Serving over 500 customers. The top 20 customers have an average of 22 repurchase orders, with a maximum of 33 repurchase orders. The top 40 customers have an average of 15 repurchase orders.